title: Immunosuppression and chemotherapeutic agents.
abstract: There are numerous immunosuppressive agents which can be divided into two major categories, specific and non-specific immunosuppressants including cytotoxic agents derived from cancer chemotherapeutics. Whenever chemotherapeutic agents which cause unintentional immunosuppression are indicated in malignancy, combination treatment with immunotherapy (immunostimulation) is encouraged.
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000477:Alkylating Agents / Q000627:therapeutic use; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D000963:Antimetabolites / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001215:Asparaginase / Q000627:therapeutic use; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D007165:Immunosuppression Therapy; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009369:Neoplasms / Q000532:radiotherapy; D011687:Purines / Q000037:antagonists & inhibitors; D011743:Pyrimidines / Q000037:antagonists & inhibitors; D013897:Thoracic Duct; D013934:Thymectomy; D014965:X-Rays
chemical_list: D000305:Adrenal Cortex Hormones; D000477:Alkylating Agents; D000903:Antibiotics, Antineoplastic; D000961:Antilymphocyte Serum; D000963:Antimetabolites; D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D007166:Immunosuppressive Agents; D011687:Purines; D011743:Pyrimidines; D001215:Asparaginase